Advanced Filter

Filter by Group

Filter by Market Availability

Displaying drugs 2201 - 2225 of 15151 in total
Alatrofloxacin is a fluoroquinolone antibiotic developed by Pfizer, delivered as a mesylate salt. It was withdrawn from the U.S. market in 2001.
Approved
Withdrawn
Matched Iupac: … [3.1.0]hexan-3-yl]-1-(2,4-difluorophenyl)-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid
Approved
Matched Iupac: … methyl-1H-1,2,3,4-tetrazol-5-yl)sulfanyl]methyl}-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy.
Approved
Matched Iupac: … -7-[(1R,2R,3R,5S)-3,5-dihydroxy-2-[(1E,3S)-3-hydroxy-3-methyloct-1-en-1-yl]cyclopentyl]hept-5-enoic acid
Matched Description: … A nonsteroidal abortifacient agent that is effective in both the first and second trimesters of pregnancy …
Matched Categories: … Genito Urinary System and Sex Hormones …
Elivaldogene autotemcel is a gene therapy consisting of genetically modified autologous cells. It is used to provide functional copies of human adrenoleukodystrophy protein (ALDP) in patients with adrenoleukodystrophy, an X-linked genetic disorder characterized by missing or non-functional ABCD1 gene that codes for ALDP. ALDP is a key protein that normally...
Approved
Matched Description: … destruction of myelin, which is an insulating layer and essential component of nerves. ... Without sufficient levels of functional ALDP, VLCFAs accumulate in the body leading to inflammation and ... It was approved by the European Commission in July 2021 under the market name Skysona, and was later …
Matched Categories: … Cellular and Gene Therapy ... Alimentary Tract and Metabolism ... Various Alimentary Tract and Metabolism Products …
Tesamorelin is a stabilized synthetic peptide analogue of the hypothalamic peptide, Growth Hormone Releasing Hormone (GHRH) indicated for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia associated with antiretroviral therapy for HIV infection.
Approved
Investigational
Matched Description: … Lipodystrophy is a metabolic condition characterized by insulin resistance, fat redistribution, and hyperlipidemia …
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …
Magnesium glycinate is a magnesium salt of glycine that is available as dietary supplements as a source of magnesium. It is used in the treatment of magnesium deficiency.
Approved
Cladribine is a purine analogue or a chlorinated derivative of adenine that causes apoptosis of B and T lymphocytes. Cladribine was first approved in the United States in 1993 initially as a treatment for a number of hematological malignancies; currently, it is approved for the treatment of hairy cell leukemia....
Approved
Investigational
Matched Description: … Cladribine is a purine analogue or a chlorinated derivative of adenine [A263733] that causes apoptosis of B and ... [A263733] In 2017 in Europe and in 2019 in the United States, cladribine was also approved for the treatment …
Matched Categories: … Antineoplastic and Immunomodulating Agents ... Nucleic Acids, Nucleotides, and Nucleosides …
Cyclic polypeptide antibiotic from Bacillus colistinus. It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes. Colistin is less toxic than Polymyxin B, but otherwise similar; the methanesulfonate is used orally.
Approved
Matched Description: … It is composed of Polymyxins E1 and E2 (or Colistins A, B, and C) which act as detergents on cell membranes …
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
An alkylating agent of value against both hematologic malignancies and solid tumors.
Approved
Investigational
Matched Description: … An alkylating agent of value against both hematologic malignancies and solid tumors. …
Matched Categories: … Antineoplastic and Immunomodulating Agents …
Synthetic peptide, 32 residues long formulated as a nasal spray.
Approved
Investigational
Matched Categories: … Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Parathyroid Hormones and Analogues ... Calcium-Regulating Hormones and Agents ... Parathyroid and Antiparathyroid Agents …
Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn from the market in 1986 due to renal toxicity caused by the medication.
Approved
Withdrawn
Matched Description: … Bucetin is an analgesic and antipyretic medication which was approved for use in Germany but was withdrawn …
Cerliponase alfa is an enzyme replacement treatment for a specific form of Batten disease. It was the first FDA-approved treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and older with late infantile neuronal ceroid lipofuscinosis type 2 (CLN2), also known as tripeptidyl...
Approved
Investigational
Matched Description: … treatment to slow loss of walking ability (ambulation) in symptomatic pediatric patients 3 years of age and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins …
Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte activation gene-3 (LAG-3).[A246165,L41265] It was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013, and has garnered interest in the treatment of a variety of cancers, including leukemia and melanoma. As immune checkpoint...
Approved
Investigational
Matched Description: … Relatlimab is a human IgG4 monoclonal antibody and novel immune checkpoint inhibitor that targets lymphocyte ... was the first commercially developed anti-LAG-3 antibody, entering clinical trials in 2013,[A246155] and ... has garnered interest in the treatment of a variety of cancers, including leukemia[A246160] and melanoma …
Matched Categories: … nivolumab and relatlimab ... Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Multiple myeloma is a cancer where plasma cells rapidly divide out of control. These cancerous cells generally express the B-cell maturation antigen, while it is rarely expressed on non-cancerous cells. Multiple myeloma is typically treated with an immunomodulatory agent like lenalidomide, a proteasome inhibitor like bortezomib, or an anti-CD38 monoclonal...
Approved
Matched Description: … [A232558,A232563,L32858] These therapies involve extracting and genetically manipulating T-cells from ... known as bb2121, is a chimeric antigen receptor (CAR) T-cell therapy like [axicabtagene ciloleucel] and ... vicleucel includes an anti-B-cell maturation antigen scFv-targeting domain, CD3ζ T-cell activation domain, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic cell and gene therapy ... Receptors, Cytoplasmic and Nuclear ... Antineoplastic and Immunomodulating Agents …
Pegvisomant is a highly selective growth hormone (GH) receptor antagonist. It is used to treat acromegaly. Unlike dopamine or somatostatin analogs (which inhibit growth hormone secretion), this drug actually blocks the hepatic (GH-mediated) production of insulin like growth factor (IGF-1), which is the main mediator of growth hormone activity.
Approved
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Anterior Pituitary Lobe Hormones and Analogues ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Elosulfase alfa is a synthetic version of the enzyme N-acetylgalactosamine-6-sulfatase. It was approved by the FDA in 2014 for the treatment of Morquio syndrome. Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizimâ„¢. The recommended dose is 2 mg per kg given intravenously over...
Approved
Investigational
Matched Description: … Elosulfase alfa was developed by BioMarin Pharmaceutical Inc. and is marketed under the brand Vimizim …
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism ... Chondroitinases and Chondroitin Lyases …
Quinagolide is a non-ergot-derived selective dopamine D2 receptor agonist used for the treatment of elevated levels of prolactin or hyperprolactinaemia. Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido, as well as long-term complications such as osteoporosis . Newer dopamine receptor agonists such as quinagolide and DB00248 are...
Approved
Investigational
Matched Description: … Hyperprolalctinaemia is associated with gonadal dysfunction, including infertility and reduced libido ... Quinagolide exists as a racemate and its relevant clinical activity is mediated predominantly by the ... It is typically present in the hydrochloride salt form and is marketed as oral tablets under the brand …
Matched Categories: … Genito Urinary System and Sex Hormones …
Sacrosidase is a liquid enzyme preparation from S.cerevisiae used for the treatment of congenital sucrose-isomaltase deficiency (CSID). People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and children. Treatment options for these patients...
Approved
Matched Description: … People with CSID have variable amounts of sucrose-isomaltase enzyme activity and therefore have issues ... Treatment options for these patients are limited and usually consists of a lifelong sucrose-free diet ... metabolizing dietary disaccharide sucrose causing chronic or intermittent watery diarrhea in infants and
Matched Categories: … Enzymes and Coenzymes ... Alimentary Tract and Metabolism …
Tibolone is a synthetic steroid hormone drug, which is mainly non-selective in its binding profile, acting as an agonist primarily at estrogen receptors (ER), with a preference for ER alpha . Tibolone (Livial, Org OD 14), produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic...
Approved
Investigational
Matched Description: … produced by Organon (West Orange, NJ), is a synthetic steroid that possesses estrogenic, androgenic and ... Tibolone is approved in 90 countries to manage menopausal symptoms and in 45 countries to prevent the ... been used in Europe for almost 2 decades, primarily for the prevention of postmenopausal osteoporosis and
Matched Categories: … Genito Urinary System and Sex Hormones ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists ... Estrogens, Antiestrogens, and Estrogen Agonist-Antagonists …
Insulin icodec is an ultra long-acting basal insulin analogue.
Approved
Investigational
Matched Categories: … Alimentary Tract and Metabolism ... Amino Acids, Peptides, and Proteins ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan was granted FDA approval...
Approved
Investigational
Matched Description: … A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and
Matched Categories: … Pituitary and Hypothalamic Hormones and Analogues ... Sex Hormones and Insulins ... Amino Acids, Peptides, and Proteins ... Somatropin and Somatropin Agonists ... Anterior Pituitary Lobe Hormones and Analogues …
Amivantamab, also known as JNJ-61186372, is an anti-EGFR-MET bispecific antibody, derived from Chinese hamster ovary cells, approved for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations, as detected by an FDA-approved test, whose...
Approved
Investigational
Matched Description: … FDA approval on 21 May 2021,[L34193] followed by the approval by the EMA on 9 December 2021 [L41474] and ... [A235103,L34193] Patients with NSCLC often develop resistance to drugs that target EGFR and MET individually ... Patients with NSCLC with exon 20 insertion mutations in EGFR do not respond to tyrosine kinase inhibitors, and
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Bazedoxifene is a third generation selective estrogen receptor modulator (SERM), developed by Pfizer following the completion of their takeover of Wyeth Pharmaceuticals. In late 2013, Pfizer received approval for bazedoxifene as part of the combination drug DUAVEE in the prevention (not treatment) of postmenopausal osteoporosis. It is approved in the...
Approved
Investigational
Matched Description: … It is approved in the European Union (marketed in Italy and Spain) and Japan as monotherapy. ... In 2013, the combination product containing conjugated estrogens and bazedoxifene was approved by the …
Matched Categories: … Genito Urinary System and Sex Hormones ... conjugated estrogens and bazedoxifene ... Sex Hormones and Modulators of the Genital System ... Hormones, Hormone Substitutes, and Hormone Antagonists …
Hydroxyethyl starch (HES/HAES) is a nonionic starch derivative. Hydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
Approved
Matched Description: … , concentration, C2/C6 ratio and Maximum Daily Dose. ... HES is a general term and can be sub-classified according to average molecular weight, molar substitution …
Matched Categories: … Blood and Related Products ... Blood and Blood Forming Organs ... Blood Substitutes and Perfusion Solutions ... Blood Substitutes and Plasma Protein Fractions …
Catumaxumab is a trifunctional monoclonal antibody developed for use in cancer treatment. It has affinity for T-cells, accessory immune cells, and cancer cells. Catumaxumab was initially authorized for market by the European Medicines Agency in April 2009 for the treatment of malignant ascites . Its market authorization was withdrawn in...
Approved
Investigational
Withdrawn
Matched Description: … It has affinity for T-cells, accessory immune cells, and cancer cells. …
Matched Categories: … Amino Acids, Peptides, and Proteins ... Antineoplastic and Immunomodulating Agents ... MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES …
Displaying drugs 2201 - 2225 of 15151 in total